A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
A phase 2 trial of Tislelizumab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by BeiGene, active and no longer recruiting.
Overview
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05635708 by BeiGene, with 400 participants planned, started 2023-03-07 and due to reach its primary completion in 2025-12-31. Interventions recorded: Tislelizumab, BGB-A445, LBL-007, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Pemetrexed, Paclitaxel / nab-paclitaxel.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialNeoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.